We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

High Cell-Free DNA Integrity Is a Biomarker for Poor Breast Cancer Survival

By LabMedica International staff writers
Posted on 12 Oct 2021
Print article
Image: Micrograph showing a lymph node invaded by ductal breast carcinoma, with an extension of the tumor beyond the lymph node (Photo courtesy of Wikimedia Commons)
Image: Micrograph showing a lymph node invaded by ductal breast carcinoma, with an extension of the tumor beyond the lymph node (Photo courtesy of Wikimedia Commons)
A team of Finnish researchers has refined a liquid biopsy analysis technique to act as a more specific biomarker in order to more accurately predict poor prognosis for patients with aggressive breast cancer.

Breast cancer (BC) research has focused lately on the utilization of cell-free DNA (cfDNA) and its concentration (cfDConc) and integrity (cfDI) as potential biomarkers. The cfDI describes the ratio of large and small cfDNA fragments. While the association of cfDConc and poor survival has already been recognized, studies on the prognostic value of cfDI have had contradictory results.

To clarify the situation, investigators at the University of Eastern Finland (Kuopio, Finland) evaluated the prognostic potential of cfDConc and cfDI in Eastern Finnish BC cases with a non-metastatic disease.

For this study, the investigators selected 204 Eastern Finnish BC cases with non-metastatic disease and isolated cfDNA from the serum collected at the time of diagnosis before any treatment was given. The cfDConc and cfDI were measured with a fluorometer and electrophoresis, and the results were analyzed together with 25 years of survival data from the Kuopio Breast Cancer Project (KBCP), which was initiated in the 1990s.

Results revealed that high cfDConc was not an independent prognostic factor, while high cfDI was found to be an independent prognostic factor for poor overall survival (OS) and breast cancer-specific survival (BCSS). Inclusion of cfDI in the commonly used multivariate logistic regression model improved the predictive performance.

The results showing that high cfDI was an independent prognostic factor for poor OS and BCSS and improved the predictive performance of logistic regression models demonstrated its prognostic potential.

“Our results show that together with traditional prognostic factors, measuring the integrity of cfDNA can in the future help us to identify breast cancer patients with a poor prognosis earlier and more accurately than before. This would allow patients requiring more intensive care to be placed under intensified care and monitoring earlier,” said senior author Dr. Arto Mannermaa, professor of clinical medicine at the University of Eastern Finland.

The study was published in the September 18, 2021, online edition of the journal Cancers.

Related Links:
University of Eastern Finland

Gold Supplier
Blood Glucose Laboratory Analyzer
Nova Primary
Cardiovascular Disease POC Analyzer
cobas h 232 POC System
SARS-CoV-2 Antigen Immunofluorescence System
Watmind SARS-CoV-2 Antigen Immunofluorescence System
Gold Supplier
BMP Whole Blood Analyzer
GEM Premier ChemSTAT

Print article



view channel
Image: The Gazelle Hb Variant Test for screening, diagnosis and management of sickle cell disease and related hemoglobinopathies at the point of care (Photo courtesy of Hemex Health)

Point-of-Care Device Accurately Rapidly Diagnoses Sickle Cell Disease

Hemoglobinopathies are the most common autosomal hereditary disorders. Approximately 7% of the global population carries hemoglobin gene mutation including structural hemoglobin variants like sickle hemoglobin... Read more


view channel
Image: The IMMULITE 2000 XPi Immunoassay System provides multiple tests on a single, easy-to-use analyzer, including the thyroid-stimulating immunoglobulin assay (Photo courtesy of Siemens Healthcare)

Immunoassays Evaluated for Thyroid-Stimulating Receptor Antibody in Graves’ Disease

Graves' disease (GD), also known as toxic diffuse goiter, is an autoimmune disease that affects the thyroid. It frequently results in and is the most common cause of hyperthyroidism and it also often results... Read more


view channel
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)

Multiplex Immunoassay Developed for Confirmation and Typing of HTLV Infections

Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated five to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated... Read more


view channel

AI Accurately Detects and Diagnoses Colorectal Cancer from Tissue Scans As Well or Better Than Pathologists

Artificial intelligence (A) can accurately detect and diagnose colorectal cancer from tissue scans as well or better than pathologists, according to a new study. The study, which was conducted by researchers... Read more


view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more


view channel

Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases

The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.